5-羟色胺与硬皮病
Serotonin and Scleroderma

作者: 黄建国 * , 龚启英 :南方医科大学附属花都医院皮肤科,广州市花都区人民医院,广州; 黄朝頔 :遵义医学院珠海校区临床医学,珠海; 李桂明 :重庆医科大学第一医院皮肤科,重庆;

关键词: 5-羟色胺硬皮病Serotonin Scleroderma

摘要:

硬皮病是自身免疫性疾病之一,以血管功能障碍、炎症和皮肤硬化为特征。5-羟色胺(5-HT)作为血管活性胺类物质,炎症介质能刺激真皮成纤维细胞增殖;5-HT/5-HT2B信号通过调控血管损伤和血小板活性从而与皮肤组织纤维化有关联。临床上采用5-HT3受体抑制剂托烷司琼(tropisetron)治疗硬皮病患者取得明显效果。研究5-HT与硬皮病的关系对治疗硬皮病将开辟一条新的途径。

Scleroderma is one of the autoimmune diseases characterized by inflammation, vascular dysfunction and skin sclerosis. As the vasoactive amine substances and inflammatory mediators, serotonin (5-HT) can stimulate the dermal fibroblast proliferation; 5-HT/5-HT2B signal are associated with skin tissue fibrosis through regulating vascular injury and platelet activity. The clinical application of tropisetron (5-HT3 receptor inhibitor) obtains obvious effects in the treatment of patients with scleroderma. Study on the relationship between 5-HT and scleroderma will inaugurate a new way for the treatment of scleroderma.

 

文章引用: 黄建国 , 龚启英 , 黄朝頔 , 李桂明 (2013) 5-羟色胺与硬皮病。 医学美容, 1, 1-5. doi: 10.12677/HJMC.2013.11001

参考文献

[1] Y. Asano. Future treatments in systemic sclerosis. The Journal of Dermatology, 2010, 37(1): 54-70.

[2] A. Slominski, A. Pisarchik, B. Zbytek, D. J. Tobin, S. Kauser and J. Wortsman. Functional activity of serotoninergic and me- latoninergic systems expressed in the skin. Journal of Cellular Physiology, 2003, 196(1): 144-153.

[3] S. Andrzej, W. Jacobo and J. T. Desmond. The cutaneous sero- toninergic/melatoninergic system: Securing a place under the sun. The FASEB Journal, 2005, 19: 176-194.

[4] M. Maes, K. Ringel, M. Kubera, M. Berk and J. Rybakowski. Increased autoimmune activity against 5-HT: A key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of de- pression. Journal of Affective Disorders, 2012, 136(3): 386-392.

[5] S. Fidalgo, D. K. Ivanov and S. H. Wood. Serotonin: From top to bottom. Biogerontology. 2013, 14(1): 21-45.

[6] T. Stratz and W. Müller. Treatment of systemic sclerosis with the 5-HT3 receptor antagonist tropisetron. Scandinavian Journal of Rheumatology—Supplement, 2004, 119: 59-62.

[7] C. Clara Dees, A. Akhmetshina, P. Zerr, N. Reich, K. Palumbo, A. Horn, A. Jüngel, C. Beyer, G. Krönke, J. Zwerina, R. Reiter, N. Alenina, L. Maroteaux, S. Gay, G. Schett, O. Distler and J. H. Distler. Platelet-derived serotonin links vascular disease and tis- sue fibrosis. The Journal of Experimental Medicine, 2011, 208(5): 961-972.

[8] B. Svejda, M. Kidd, F. Giovinazzo, K. Eltawil, B. I. Gustafsson, R. Pfragner and I. M. Modlin. The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell prolifera- tion and the modulation of the fibroblast component of the neo- plastic microenvironment. Cancer, 2010, 116(12): 2902-2912.

[9] L. Dupuis, O. Spreux-Varoquaux, G. Bensimon, P. Jullien, L. Lacomblez, F. Salachas, G. Bruneteau, P. F. Pradat, J. P. Loeffler and V. Meininger. Platelet serotonin level predicts survival in amyotrophic lateral sclerosis. PLoS One, 2010, 5(10): e13346.

[10] J. Sicińska, L. Rudnicka. Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment. Polski Merkuriusz Lekarski, 2008, 25(146): 196-200.

[11] J. Wipff, P. Bonnet, B. Ruiz, P. Dieude, J. Avouac, K. Tiev, E. Hachulla, J. L. Cracowski, E. Diot, J. Sibilia, L. Mouthon, O. Meyer, A. Kahan, C. Boileau and Y. Allanore. Association study of serotonin transporter gene (SLC6A4) in systemic sclerosis in European Caucasian populations. The Journal of Rheumatology, 2010, 37(6): 1164-1167.

[12] 苏有明, 徐阳, 杨蓉娅, 宋克敏 王文岭. 限局性硬皮病患者血清5-羟色胺测定[J]. 中国现代实用医学杂志, 2006, 1(7): 65-66.

[13] L. Beretta, M. Cossu, M. Marchini, F. Cappiello, A. Artoni, G. Motta and R. Scorza. A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation. Arthritis Research & Therapy, 2008, 10(5): R103.

[14] I. Kajihara, M. Jinnin, T. Makino, S. Masuguchi, K. Sakai, S. Fukushima, K. Maruo, Y. Inoue and H. Ihn. Overexpression of hepatocyte growth factor receptor in scleroderma dermal fibro- blasts is caused by autocrine transforming growth factor β sig- naling. BioScienceTrends, 2012, 6(3): 136-142.

[15] É. Szekanecz, S. Szamosi, Á. Horváth, Á. Németh, B. Juhász, J. Szántó, G. Szücs and Z. Szekanecz. Malignancies associated with systemic sclerosis. Autoimmunity Reviews, 2012, 11(12): 852-855.

[16] M. Bonifazi, I. Tramacere, G. Pomponio, B. Gabrielli, E. V. Av- vedimento, C. La Vecchia, E. Negri and A. Gabrielli. Systemic sclerosis (scleroderma) and cancer risk: Systematic review and meta-analysis of observational studies. Rheumatology (Oxford), 2013, 52(1): 143-154.

[17] Ø. Hauso, B. I. Gustafsson, J. P. Loennechen, A. K. Stunes, I. Nordrum and H. L. Waldum. Long-term serotonin effects in the rat are prevented by terguride. Regulatory Peptides, 2007, 143 (1-3): 39-46.

[18] S. Henness, F. M. Wigley. Current drug therapy for scleroderma and secondary Raynaud’s phenomenon: Evidence-based review. Current Opinion in Rheumatology, 2007, 19(6): 611-618.

[19] 陈新谦. 新编药物学(16版)[M]. 北京: 人民卫生出版社, 2007: 286-299.

[20] K. Nordlind, E. C. Azmitia and A. Slominski. The skin as a mirror of the soul: Exploring the possible roles of serotonin. Experimental Dermatology, 2008, 17(4): 301-311.

[21] A. Leask. Emerging targets for the treatment of scleroderma. Expert Opinion on Emerging Drugs, 2012, 17(2): 173-179.

[22] H. Kirsten, J. Burkhardt, H. Hantmann, N. Hunzelmann, P. Vaith, P. Ahnert and I. Melchers. 5HT2A polymorphism His452Tyr in a German Caucasian systemic sclerosis population. Arthritis Re- search & Therapy, 2009, 11(2): 403.

分享
Top